All In Biotech

Drug Trial Radar · NCT04559139

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Feb 24, 2021

Primary completion

Jul 1, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Sep 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.

Conditions

  • Stage II Gallbladder Cancer AJCC v8
  • Stage IIA Gallbladder Cancer AJCC v8
  • Stage IIB Gallbladder Cancer AJCC v8
  • Stage III Gallbladder Cancer AJCC v8
  • Stage IIIA Gallbladder Cancer AJCC v8
  • Stage IIIB Gallbladder Cancer AJCC v8

Interventions

  • CisplatinDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • LymphadenectomyProcedure

    Undergo portal lymphadenectomy

  • Partial HepatectomyProcedure

    Undergo partial hepatectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in overall survivalTime frame: Time from randomization to death or last follow-up, assessed up to 5 years

Locations

367 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mercy Cancer Center - Carmichael

    Carmichael, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Providence Queen of The Valley

    Napa, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Mercy Cancer Center - Rocklin

    Rocklin, California

  • Mercy Cancer Center - Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California

  • Providence Medical Foundation - Santa Rosa

    Santa Rosa, California

  • Providence Santa Rosa Memorial Hospital

    Santa Rosa, California

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California

  • Torrance Memorial Medical Center

    Torrance, California

  • Woodland Memorial Hospital

    Woodland, California

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado

  • Saint Francis Cancer Center

    Colorado Springs, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Mercy Medical Center

    Durango, Colorado

  • Southwest Oncology PC

    Durango, Colorado

Showing 40 of 367 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.